View Item 

Show simple item record

Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements
dc.contributor.authorBonkovsky, Herbert L.
dc.contributor.authorKleiner, David E.
dc.contributor.authorGu, Jiezhun
dc.contributor.authorOdin, Joseph A.
dc.contributor.authorRusso, Mark W.
dc.contributor.authorNavarro, Victor M.
dc.contributor.authorFontana, Robert J.
dc.contributor.authorGhabril, Marwan S.
dc.contributor.authorBarnhart, Huiman
dc.contributor.authorHoofnagle, Jay H.
dc.date.accessioned2017-04-14T15:11:57Z
dc.date.available2018-05-15T21:02:51Zen
dc.date.issued2017-04
dc.identifier.citationBonkovsky, Herbert L.; Kleiner, David E.; Gu, Jiezhun; Odin, Joseph A.; Russo, Mark W.; Navarro, Victor M.; Fontana, Robert J.; Ghabril, Marwan S.; Barnhart, Huiman; Hoofnagle, Jay H. (2017). "Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements." Hepatology 65(4): 1267-1277.
dc.identifier.issn0270-9139
dc.identifier.issn1527-3350
dc.identifier.urihttps://hdl.handle.net/2027.42/136514
dc.publisherWiley Periodicals, Inc.
dc.titleClinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelInternal Medicine and Specialties
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/136514/1/hep28967.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/136514/2/hep28967_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/136514/3/hep28967-sup-0001-suppinfo.pdf
dc.identifier.doi10.1002/hep.28967
dc.identifier.sourceHepatology
dc.identifier.citedreferenceHayashi PH, Rockey D, Fontana RJ, Tillmann HL, Kaplowitz N, Barnhart H, et al.; for the Drug Induced Liver Injury Network Investigators. Death and liver transplantation within two years of onset of drug‐induced liver injury. Hepatology (submitted).
dc.identifier.citedreferenceDegott C, Feldmann G, Larrey D, Durand‐Schneider AM, Grange D, Machayekhi JP, et al. Drug‐induced prolonged cholestasis in adults: a histological semiquantitative study demonstrating progressive ductopenia. Hepatology 1992; 15: 244 – 251.
dc.identifier.citedreferenceForbes GM, Jeffrey GP, Shilkin KB, Reed WD. Carbamazepine hepatotoxicity: another cause of the vanishing bile duct syndrome. Gastroenterology 1992; 102: 1385 – 1388.
dc.identifier.citedreferenceDavies MH, Harrison RF, Elias E, Hübscher SG. Antibiotic‐associated acute vanishing bile duct syndrome: a pattern associated with severe, prolonged, intrahepatic cholestasis. J Hepatol 1994; 20: 112 – 116.
dc.identifier.citedreferenceRichardet JP, Mallat A, Zafrani ES, Blazquez M, Bognel JC, Campillo B. Prolonged cholestasis with ductopenia after administration of amoxicillin/clavulanic acid. Dig Dis Sci 1999; 44: 1997 – 2000.
dc.identifier.citedreferenceSmith LA, Ignacio JR, Winesett MP, Kaiser GC, Lacson AG, Gilbert‐Barness E, et al. Vanishing bile duct syndrome: amoxicillin‐clavulanic acid associated intra‐hepatic cholestasis responsive to ursodeoxycholic acid. J Pediatr Gastroenterol Nutr 2005; 41: 469 – 473.
dc.identifier.citedreferenceVuppalanchi R, Chalasani N, Saxena R. Restoration of bile ducts in drug‐induced vanishing bile duct syndrome due to zonisamide. Am J Surg Pathol 2006; 30: 1619 – 1623.
dc.identifier.citedreferenceJuricic D, Hrstic I, Radic D, Skegro M, Coric M, Vucelic B, Francetic I. Vanishing bile duct syndrome associated with azithromycin in a 62‐year‐old man. Basic Clin Pharmacol Toxicol 2010; 106: 62 – 65.
dc.identifier.citedreferenceRobinson W, Habr F, Manlolo J, Bhattacharya B. Moxifloxacin associated vanishing bile duct syndrome. J Clin Gastroenterol 2010; 44: 72 – 73.
dc.identifier.citedreferenceBhayana H, Appasani S, Thapa BR, Das A, Singh K. Lamotrigine induced vanishing bile duct syndrome in a child. J Pediatr Gastroenterol Nutr 2012; 55: e147 – e148.
dc.identifier.citedreferenceReau NS, Jensen DM. Vanishing bile duct syndrome. Clin Liver Dis 2008; 12: 203 – 217.
dc.identifier.citedreferenceHoofnagle JH. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. http://livertox.nih.gov/Phenotypes. Accessed October 20, 2016.
dc.identifier.citedreferenceFontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, Rochon J; for the US DILIN Investigators. Drug‐Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. [Paper # 03 from the US Drug Induced Liver Injury Network] Drug Saf 2009; 32: 55 – 68.
dc.identifier.citedreferenceChalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, et al.; for the US DILIN Investigators. Features and outcomes of 899 patients with drug‐induced liver injury: the DILIN Prospective Study. [Paper # 36 from the US Drug Induced Liver Injury Network] Gastroenterology 2015; 148: 1340 – 1352.
dc.identifier.citedreferenceRockey DC, Seeff LB, Rochon J, Freston J, Chalasani N, Bonacini M, et al.; for the US DILIN Investigators. Causality assessment in drug‐induced liver injury using a structured expert opinion process: comparison to the Roussel‐Uclaf causality assessment method. [Paper # 07 from the US Drug Induced Liver Injury Network] Hepatology 2010; 51: 2117 – 2126.
dc.identifier.citedreferenceKleiner DE, Chalasani NP, Lee WM, Fontana RJ, Bonkovsky HL, Watkins PB, et al.; for the US DILIN Investigators. Hepatic histological findings in suspected drug‐induced liver injury: systematic evaluation and clinical associations. [Paper # 23 from the US Drug Induced Liver Injury Network] Hepatology 2014; 59: 661 – 670.
dc.identifier.citedreferencedeLemos A, Ghabril M, Rockey DC, Gu J, Barnhart H, Fontana RJ, et al.; for the US DILIN Investigators. Amoxicillin‐clavulanate‐induced liver injury. [Paper # 40 from the US Drug‐Induced Liver Injury Network] Dig Dis Sci 2016; 61: 2406 – 2416.
dc.identifier.citedreferenceMoy BT, Dojki FK, Scholes JV, Hoffman MG. Azithromycin‐induced cholestatic hepatitis. Conn Med 2015; 79: 213 – 215.
dc.identifier.citedreferenceOrman ES, Conjeevaram HS, Vuppalanchi R, Freston JW, Rochon J, Kleiner DE, et al.; for the US DILIN Investigators. Clinical and histopathological features of fluoroquinolone‐induced liver injury. [Paper # 10 from the US Drug Induced Liver Injury Network] Clin Gastroenterol Hepatol 2011; 9: 517 – 523.
dc.identifier.citedreferenceGrant LM, Kleiner DE, Conjeevaram HS, Vuppalanchi R, Lee WM. Clinical and histological features of idiosyncratic acute liver injury caused by temozolomide. [Paper # 18 from the US Drug Induced Liver Injury Network] Dig Dis Sci 2013; 58: 1415 – 1421.
dc.identifier.citedreferenceSarganas G, Orzechowski HD, Klimpel A, Thomae M, Kauffmann W, Herbst H, et al. Severe sustained cholestatic hepatitis following temozolomide in a patient with glioblastoma multiforme: case study and review of data from the FDA adverse events reporting system. Neuro Oncol 2012; 14: 541 – 546.
dc.identifier.citedreferenceMason M, Adeyi O, Fung S, Millar BA. Vanishing bile duct syndrome in the context of concurrent temozolomide for glioblastoma. BMJ Case Rep 2014 Nov 28. pii: bcr2014208117. doi: 10.1136/bcr-2014-208117.
dc.identifier.citedreferenceDesmet VJ. Histopathology of chronic cholestasis and adult ductopenic syndrome. Clin Liver Dis 1998; 2: 249 – 264.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
hep28967.pdf
Size:
474.1KB
Format:
PDF
View/Open
Name:
hep28967_am.pdf
Size:
5.838MB
Format:
PDF
View/Open
Name:
hep28967-sup-0001-suppinfo.pdf
Size:
4.283MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.